Current immunotherapy methods aim to enhance immune function against tumor cells, utilizing diverse approaches such as blocking PD-1, PD-L1, and CTLA4, using cancer vaccines, or administering engineered immune cells, such as natural killer (NK) cells or CAR T cells. This evidence concerns the gene CTLA4 and cancer.